Open Access Highly Accessed Open Badges Research article

Spectral-domain optical coherence tomography evaluation of postoperative cystoid macular oedema following phacoemulsification with intraoperative complication

Keat Ween Khaw1*, Hee Hong Lam1, Tsung Fei Khang2, Azida Juana Wan Ab Kadir1 and Visvaraja Subrayan1

Author Affiliations

1 Department of Ophthalmology, University of Malaya Medical Centre, Lembah Pantai, Kuala Lumpur 59100, Malaysia

2 Institute of Mathematical Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia

For all author emails, please log on.

BMC Ophthalmology 2014, 14:16  doi:10.1186/1471-2415-14-16

Published: 17 February 2014



To report the rate of cystoid macular oedema (CMO) as detected by spectral-domain optical coherence tomography (SD-OCT) after intraoperative complication during phacoemulsification. The secondary objectives include comparing mean macular thickness and best-corrected visual acuity (BCVA) between those who developed postoperative CMO against those who did not.


This is a prospective cohort study conducted in a tertiary hospital between July 2009 and June 2010. Serial SD-OCT and BCVA were performed at baseline, 1 week, 6 weeks and 16 weeks postoperatively.


Single eyes from 47 subjects were analyzed; of these 16 (34%) eyes developed CMO. In the CMO group, mean macular thickness (±SD) increased sharply by 56 μm from 273 ± 24 μm at baseline to 329 ± 31 μm at 16 weeks; whereas in the non-CMO group, macular thickness showed a slight increase of 14 μm from 259 ± 21 μm to 272 ± 20 μm. In the CMO group, mean BCVA (in logarithm of minimum angle of resolution) improved modestly from 0.92 ± 0.66 to 0.66 ± 0.41 at week 16; while in the non-CMO group, mean BCVA improved markedly from 0.98 ± 0.59 to 0.21 ± 0.13. The two groups differed significantly in mean macular thickness (p < 0.001) and mean BCVA (p < 0.001) at 16 weeks.


As detection rate of CMO is high, postoperative OCT monitoring for patients with intraoperative complications allows earlier diagnosis and treatment.

Cystoid macular oedema; Spectral-domain optical coherence tomography; Phacoemulsification; Intraoperative complication